
Treatment GuideJust DiagnosedSex & DatingAfrican AmericanStigmaAsk the HIV DocPrEP En EspañolNewsVoicesPrint IssueVideoOut 100
CONTACTCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2025 Pride Publishing Inc.
All Rights reserved
All Rights reserved
Scroll To Top
By continuing to use our site, you agree to our Privacy Policy and Terms of Use.
In my latest article I wrote about the three newest drugs we have been blessed with: Intelence, Isentress, and Selzentry. All were approved by the Food and Drug Administration based on 24-week data from clinical trials, which means that enough patients had their viralload reduced to less than 50 after six months that the FDA was willing to approve the drug while more long-term results were collected. So it was reassuring to hear at this year's Conference on Retroviruses and Opportunistic Infections that the 48-week data confirmed their effectiveness. Selzentry and Isentress were approved in the second half of 2007, and each was the first drug in a totally new class of antiretrovirals. Intelence, approved in January, is a nonnucleoside reverse transcriptase inhibitor, like Sustiva and Viramune, but because it has resistance mutations different from the other nonnukes, it has the potential to have an impact on treatment options that are nearly the same as having another new drug class available. With Sustiva and Viramune, one single mutation at location K103N causes complete loss of anti-HIV activity by both drugs. Needless to say, K103N is now a common mutation. Intelence, on the other hand, is not affected by K103N. In fact, of the 12 nonnuke-resistant mutations defined by the International AIDS Society, it takes three or more mutations to reduce the effectiveness of this drug. In essence, it can resurrect the nonnucleoside class. As with Selzentry and Isentress, Intelence was approved based on a trial of three-class-resistant patients who were given an optimized salvage regimen with either Intelence or a placebo. At 48 weeks 61% of the patients on Intelence had undetectable viral loads compared to 40% who were given a placebo. Interestingly, in patients whose salvage regimen contained no other active drug, Intelence by itself got 45% of them to undetectability. Intelence is dosed as two tablets to be taken twice a day with food. A rash occurred in 17% of patients, mostly between weeks two and four, but only 2% of patients stopped the drug due to the rash. Nausea occurred in 14% of patients versus 11% of patients who were on a placebo (remember these were multidrug salvage regimens that they were being given). The one issue with this drug is its somewhat complicated metabolism pathways, which limit its combining options. While Intelence can be combined with any nucleoside reverse transcriptase inhibitor, the only protease inhibitors that it can be used with are Invirase or Prezista (each boosted) or with Kaletra. And it cannot be combined with any of the other nonnucleosides. Despite theses restrictions, we can extend a warm welcome to this newest kid on the block.
From our Sponsors
Most Popular
Lexi Love comes out as HIV+ after Trump deletes federal resources
January 23 2025 11:23 AM
Grindr is reminding us why jockstraps are so sexy and iconic
May 02 2025 5:36 PM
BREAKING NEWS: Trump admin moves to end federal HIV prevention programs
March 18 2025 6:10 PM
Trump's orders prompt CDC to erase HIV resources
January 31 2025 5:29 PM
Celebrating Black History Month with our annual African American issue
February 01 2025 3:28 PM
Tyler TerMeer vows to continue to fight for health care for all
January 28 2025 3:00 PM
Discover the power of Wellness in your life
March 26 2025 12:41 PM
Plus: Featured Video
Latest Stories
Dancer. Healer. Survivor. DéShaun Armbrister is all of the above
July 02 2025 8:23 PM
Two right-wing Supreme Court justices signal they may uphold access to PrEP and more
April 21 2025 4:10 PM
Broadway's best raise over $1 million for LGBTQ+ and HIV causes
April 03 2025 7:15 PM
Plus nominated for 2025 GLAAD Media Award
January 22 2025 12:42 PM
'RuPaul's Drag Race' star Trinity K Bonet quietly comes out trans
December 15 2024 6:27 PM
AIDS Memorial Quilt displayed at White House for the first time
December 02 2024 1:21 PM
BREAKING: Supreme Court rules to save free access to preventive care, including PrEP
June 27 2025 10:32 AM
1985: the year the AIDS crisis finally broke through the silence
June 26 2025 11:24 AM
Trump admin guts $258 million in funding for HIV vaccine research
June 03 2025 3:47 PM
500,000 Children at Risk: PEPFAR Funding Crisis
April 08 2025 3:51 PM
The Talk Season 5 premieres this spring with HIV guidance for the newly diagnosed
March 26 2025 1:00 PM
Jess King is here to help you live your happiest, healthiest life yet
March 24 2025 4:35 PM
A camp for HIV-positive kids is for sale. Here's why its founder is celebrating
January 02 2025 12:21 PM
VIDEO: A man living with HIV discusses his journey to fatherhood
June 10 2025 4:58 PM
HRC holds 'die-in' to protest Trump health care cuts
April 28 2025 2:11 PM
Season 4 of The Switch on resilience & radical self-love returns this spring
March 26 2025 12:20 PM
Gerald Garth is keeping people of color happy and healthy through trying times
March 11 2025 3:38 PM
This long-term HIV survivor says testosterone therapy helped save his life.
December 16 2024 8:00 PM
Ricky Martin delivers showstopping performance for 2024 World AIDS Day
December 05 2024 12:08 PM